La FDA ha aprobado varios agonistas del receptor GLP-1 para indicaciones especficas, principalmente administrados mediante inyeccin subcutnea, con la excepcin de una formulacin oral
Women should discontinue GLP-1 medications before conception or as soon as pregnancy is confirmed, with semaglutide requiring cessation at least 2 months before planned pregnancy
Integument: Solitary, brown or blackish-brown, roundish-oval or bizarre, peripherally growing, (not palpable) inhomogeneous spot or patch of varying colour intensity
Doctors usually follow FDA rules for prescribing these medicines
What are the most common side effects of GLP-1 therapy in elderly patients
Outcomes vary, and your baseline risk factors matter a lot